

FOI 2140

01/02/2024

FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST

How many patients were treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:

- Adalimumab - Humira
- Adalimumab Biosimilar
- Apremilast
- Bimekizumab
- Brodalumab
- Certolizumab
- Deucravacitinib
- Dimethyl fumarate
- Etanercept - Enbrel
- Etanercept Biosimilar
- Guselkumab
- Infliximab - Remicade
- Infliximab Biosimilar
- Ixekizumab
- Risankizumab
- Secukinumab
- Tildrakizumab
- Ustekinumab

Adalimumab - Humira	34
Adalimumab Biosimilar	259
Apremilast	0
Bimekizumab	1
Brodalumab	8
Certolizumab	8
Deucravacitinib	0
Dimethyl fumarate	0
Etanercept - Enbrel	1
Etanercept Biosimilar	2
Guselkumab	68
Infliximab - Remicade	0
Infliximab Biosimilar	8
Ixekizumab	96
Risankizumab	58



Southern Health
and Social Care Trust

Secukinumab	29
Tildrakizumab	8
Ustekinumab	27

Email: Foi.Team@Southerntrust.hscni.net